1. Lung and bone metastases patterns in Ewing sarcoma: Chemotherapy improves overall survival.
- Author
-
Liu B and Tang L
- Subjects
- Humans, Male, Female, Adult, Adolescent, Young Adult, SEER Program, Child, Middle Aged, Kaplan-Meier Estimate, Prognosis, Risk Factors, Brain Neoplasms secondary, Brain Neoplasms drug therapy, Brain Neoplasms mortality, Retrospective Studies, Neoplasm Staging, Child, Preschool, Sarcoma, Ewing drug therapy, Sarcoma, Ewing mortality, Sarcoma, Ewing pathology, Bone Neoplasms secondary, Bone Neoplasms drug therapy, Bone Neoplasms mortality, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Lung Neoplasms secondary, Lung Neoplasms mortality
- Abstract
Ewing sarcoma (ES) is a small round cell malignancy, mainly in the bone tissue, followed by the soft tissue. Lung metastases (LM) and bone metastases (BM) are the most common types of metastases. From 2010 to 2018, the Surveillance, Epidemiology, and End Results database diagnosed 242 cases of ES with LM, 186 cases of ES with BM, and 74 cases of ES with LM and BM. Univariate and multivariate logistic regression analyses were used to determine the risk factors for LM and/or BM, and Kaplan-Meier curves and Cox regression analysis were used to determine the prognostic factors for LM and/or BM. Tumor size ≥50 mm, N1 stage, BM, liver metastases, and surgical treatment were significantly correlated with LM; tumor size >100 mm, brain metastases, LM, surgical treatment, and chemotherapy were significantly correlated with BM; female, N1 stage, brain metastases, liver metastases, and surgical treatment were significantly correlated with LM and BM. Older age, BM, higher T stage, no surgical treatment, and no chemotherapy were harmful to the survival of ES patients with LM; older age, female, LM, and no chemotherapy were harmful to the survival of ES patients with BM; older age and no chemotherapy were harmful to the survival of ES patients with LM and BM. Larger tumor size, N1 stages, and organ metastases were significantly associated with ES patients with LM and/or BM. Chemotherapy is effective in improving the survival., Competing Interests: The authors have no funding and conflicts of interest to disclose., (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF